|
Market Closed -
Hong Kong S.E.
12:08:05 09/11/2026 +04
|
5-day change | 1st Jan Change | ||
| 3.000 HKD | 0.00% |
|
-3.23% | +1.69% |
| 08-31 | HighTide Therapeutics, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 07-02 | HighTide Therapeutics, CEO Terminate Loan Contract on Bourse's Concerns | MT |
Company Valuation: HighTide Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2023 | 2024 | 2025 |
|---|---|---|---|
| Market Cap 1 | 6,056 | 614.3 | 1,515 |
| Change | - | -89.86% | 146.54% |
| Enterprise Value (EV) 1 | 5,336 | 201.5 | 1,139 |
| Change | - | -96.22% | 464.94% |
| P/E | -3.25x | -1.41x | -5.19x |
| PBR | 8.62x | 1.45x | 4.93x |
| PEG | 0.2x | 0x | 0.1x |
| Capitalization / Revenue | - | - | - |
| EV / Revenue | - | - | - |
| EV / EBITDA | -11.9x | -0.45x | -5.13x |
| EV / EBIT | -11.9x | -0.45x | -5.09x |
| EV / FCF | - | - | - |
| FCF Yield | - | - | - |
| Dividend per Share 2 | - | - | - |
| Rate of return | - | - | - |
| EPS 2 | -3.617 | -0.8445 | -0.5106 |
| Distribution rate | - | - | - |
| Net sales | - | - | - |
| EBITDA 1 | -447.7 | -443.7 | -222.2 |
| EBIT 1 | -448.2 | -444.8 | -223.6 |
| Net income 1 | -939.3 | -381.8 | -245 |
| Net Debt 1 | -719.9 | -412.8 | -376 |
| Reference price 2 | 11.764 | 1.193 | 2.651 |
| Nbr of stocks (in thousands) | 514,771 | 514,771 | 571,326 |
| Announcement Date | 26/04/24 | 23/04/25 | 29/04/26 |
1CNY in Million2CNY
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 256M | |
| 17.43x | 6.68x | 12.81x | 1.71% | 66.7B | |
| 30.07x | 8.27x | 26.77x | 0.07% | 56.88B | |
| 38.45x | 6.84x | 20.45x | 0.85% | 56.53B | |
| 46.55x | 6.14x | 30.16x | -.--% | 46.49B | |
| 35.48x | 3.35x | 14.48x | -.--% | 44.8B | |
| -22.71x | 62.58x | -21.48x | -.--% | 41.59B | |
| 35.87x | 8.84x | 23.03x | 0.37% | 35.35B | |
| 41.46x | 8.08x | 26.8x | -.--% | 33.29B | |
| -69.81x | 13.21x | -71.01x | -.--% | 25.1B | |
| Average | 16.98x | 13.78x | 6.89x | 0.33% | 41B | |
| Weighted average by Cap. | 21.52x | 12.92x | 11.34x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 2511 Stock
- Valuation HighTide Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
